Swiss National Bank Buys 22,600 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Swiss National Bank lifted its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Rating) by 8.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 292,760 shares of the biopharmaceutical company’s stock after purchasing an additional 22,600 shares during the quarter. Swiss National Bank owned about 0.20% of Sangamo Therapeutics worth $1,701,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. C M Bidwell & Associates Ltd. bought a new position in Sangamo Therapeutics during the fourth quarter valued at $40,000. Point72 Hong Kong Ltd purchased a new stake in Sangamo Therapeutics in the 4th quarter worth about $46,000. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Sangamo Therapeutics during the first quarter valued at approximately $100,000. Sandbox Financial Partners LLC bought a new position in shares of Sangamo Therapeutics during the first quarter valued at approximately $144,000. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Sangamo Therapeutics by 22.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 22,227 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 4,141 shares during the period. Institutional investors own 57.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on SGMO. Wedbush reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, June 13th. cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 11th.

Sangamo Therapeutics Stock Down 0.7 %

Shares of NASDAQ:SGMO opened at $5.53 on Friday. The business’s 50 day moving average is $4.95 and its 200 day moving average is $4.89. The stock has a market cap of $865.74 million, a P/E ratio of -4.72 and a beta of 1.41. Sangamo Therapeutics, Inc. has a 52-week low of $3.12 and a 52-week high of $11.49.

Sangamo Therapeutics (NASDAQ:SGMOGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. Sangamo Therapeutics had a negative return on equity of 48.06% and a negative net margin of 150.96%. The firm had revenue of $29.38 million for the quarter, compared to analyst estimates of $24.63 million. During the same quarter last year, the firm posted ($0.33) earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, sell-side analysts anticipate that Sangamo Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling at Sangamo Therapeutics

In other news, major shareholder Biogen Inc. sold 400,000 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $5.33, for a total value of $2,132,000.00. Following the completion of the sale, the insider now owns 23,752,466 shares of the company’s stock, valued at approximately $126,600,643.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.60% of the company’s stock.

Sangamo Therapeutics Company Profile

(Get Rating)

Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Further Reading

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with's FREE daily email newsletter.